Thalidomide - A revival story.

被引：170

作者：

Raje, N ^{[1
]}

Anderson, K ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 1999年 / 341卷 / 21期

关键词：

D O I：

10.1056/NEJM199911183412110

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1606 / 1609

页数：4

共 17 条

[1]

[Anonymous], 1998, J Clin Oncol, V16, P3832

[2] A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].

Attal, M ;

Harousseau, JL ;

Stoppa, AM ;

Sotto, JJ ;

Fuzibet, JG ;

Rossi, JF ;

Casassus, P ;

Maisonneuve, H ;

Facon, T ;

Ifrah, N ;

Payen, C ;

Bataille, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97

[3]

Bellamy WT, 1999, CANCER RES, V59, P728

[4]

Corral LG, 1999, J IMMUNOL, V163, P380

[5] THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].

DAMATO, RJ ;

LOUGHNAN, MS ;

FLYNN, E ;

FOLKMAN, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085

[6] Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines [J].

Damiano, JS ;

Cress, AE ;

Hazlehurst, LA ;

Shtil, AA ;

Dalton, WS .

BLOOD, 1999, 93 (05) :1658-1667

[7] Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade [J].

Geitz, H ;

Handt, S ;

Zwingenberger, K .

IMMUNOPHARMACOLOGY, 1996, 31 (2-3) :213-221

[8] Thalidomide on the comeback trail [J].

Hales, BF .

NATURE MEDICINE, 1999, 5 (05) :489-490

[9] Multiple myeloma: Increasing evidence for a multistep transformation process [J].

Hallek, M ;

Bergsagel, PL ;

Anderson, KC .

BLOOD, 1998, 91 (01) :3-21

[10] Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset [J].

Haslett, PAJ ;

Corral, LG ;

Albert, M ;

Kaplan, G .

JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (11) :1885-1892

← 1 2 →